NeuraLight and NeuroSense Partner to Use Novel Biomarkers for ALS Drug Development
NeuraLight announced a collaboration with NeuroSense Therapeutics (NASDAQ: NRSN) to advance the development of objective biomarkers for monitoring amyotrophic lateral sclerosis (ALS) disease progression
Partnership Details
Clinical scales such as ALSFRS-R are limited by subjectivity and variability, slowing the path to effective therapies. NeuraLight’s biomarkers are designed to:
- Monitor disease progression
- Detect subtle progression earlier than clinical scales
- Improve trial power and patient stratification
- Reduce sample sizes and trial duration
- Support the development of disease-modifying therapies for ALS and related conditions
Leadership Perspectives
Alon Ben-Noon, CEO, NeuroSense: “Precise biomarkers are critical for ... tracking neurodegenerative diseases. We believe this collaboration can improve patient stratification and increase the likelihood of success in future pivotal trials of PrimeC.”
Dr. Rivka Kreitman, Chief Innovation Officer, NeuraLight: “Through this partnership, we aim to demonstrate that oculometrics provide an objective, reliable, and replicable measure of ALS progression. Validating these tools will improve trial success rates while reducing costs and complexity.”